Sorrento Therapeutics (SRNE) has been beaten down lately with too much selling pressure. While the stock has lost 77.2% over the past four weeks, there is light at the end of the tunnel as it is now ...
Sorrento Therapeutics stock currently trades at a fraction of a cent as of September 18, 2026, underscoring its micro-cap status in the biotechnology sector. Recent data highlight the company’s very ...
Sorrento Therapeutics just posted a 26% rise in quarterly sales for its ZTlido drug Sorrento Therapeutics Inc (NASDAQ:SRNE) is making another run up the charts today, thanks to the biotech's strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results